The Journal of Clinical Endocrinology & Metabolism · 2023 · 16 citations · 12 references
Veterinary MedicineOncologyBone MetabolismCarcinogenesisNeoplasiaBenign TumorsBone PathologyBone TumorsMalignant NeoplasmsMalignant TumorsMesenchymal TumorsBenign Mesenchymal TumorsCochrane Review MethodologyFibroblast Growth Factor 23 DysregulationSystematic Review RetrievalTumor-induced Osteomalacia
CONTEXT: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome usually caused by oversecretion of fibroblast growth factor 23 (FGF23) from a phosphaturic mesenchymal tumor (PMT). PMTs are usually benign neoplasms but some of them show malignant characteristics. OBJECTIVE: The aim of this study was to compare the clinical characteristics of benign and malignant PMTs inducing TIO. METHODS: On March 31, 2023, we performed a systematic review of individual patient data analysis in Medline, Google Scholar, Google book, and Cochrane Library using the terms "tumor induced osteomalacia," "oncogenic osteomalacia," "hypophosphatemia," with no language restrictions and according to Preferred Reporting Items for Systematic reviews and Meta-Analyses criteria. RESULTS: Overall, we collected data from 837 patients with TIO in which the diagnosis of benign and malignant PMT was specified. Of them, 89 were affected by malignant PMT and 748 by benign PMT. Patients with malignant PMTs were younger and presented bone pain, functional impairment, and bone deformities more frequently. Malignant PMTs showed higher values of intact FGF23 and a higher mortality rate. CONCLUSION: The study results identify the clinical characteristics of patients with malignant TIO, permitting the early identification of patients with PMT at increased risk of malignancy. This may significantly improve the diagnostic approach to disease. Further experimental studies are mandatory to clarify the role of FGF23 in the pathogenesis of malignancy in PMTs.
12
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Yohann Loriot, Andrea Necchi, Se Hoon Park et al. · New England Journal of Medicine · 2019 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +15
Vardit Lavi-Moshayoff, Gilad Wasserman, Tomer Meir et al. · American Journal of Physiology-Renal Physiology · 2010 · 448 citations
Medicine, Endocrinology, Nephrology +15
Burosumab for the Treatment of Tumor-Induced Osteomalacia
Suzanne M. Jan de Beur, Paul D. Miller, Thomas J. Weber et al. · Journal of Bone and Mineral Research · 2020 · 179 citations · Full text
Medicine, Endocrinology, Oncology +17